Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie Acquires 5,000 Shares

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie purchased 5,000 shares of Septerna stock in a transaction on Friday, February 21st. The stock was bought at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the transaction, the chief financial officer now directly owns 30,000 shares in the company, valued at $175,500. This represents a 20.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Septerna Trading Down 1.5 %

NASDAQ:SEPN opened at $5.80 on Friday. The stock’s 50 day moving average price is $17.78. Septerna, Inc. has a 52-week low of $4.17 and a 52-week high of $28.99.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. JPMorgan Chase & Co. started coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price target on the stock. TD Cowen started coverage on Septerna in a research report on Tuesday, November 19th. They set a “buy” rating on the stock. Wells Fargo & Company lowered Septerna from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $43.00 to $14.00 in a research report on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 target price on shares of Septerna in a research report on Tuesday, February 11th.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC purchased a new position in shares of Septerna in the 4th quarter valued at approximately $25,419,000. TRV GP V LLC purchased a new position in shares of Septerna in the 4th quarter valued at approximately $142,337,000. TRV GP VI LLC purchased a new position in shares of Septerna in the 4th quarter valued at approximately $72,191,000. Vanguard Group Inc. purchased a new position in shares of Septerna in the 4th quarter valued at approximately $22,557,000. Finally, Corebridge Financial Inc. acquired a new stake in shares of Septerna in the 4th quarter valued at approximately $212,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.